Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 7;15(4):706-712.
doi: 10.22088/cjim.15.4.706. eCollection 2024 Fall.

Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study

Sarvin Alizadeh Sadighi  1 , Nematollah Rostami  2 , Maryam Tohidi  3 , Mahbobeh Mashayekhi  4
Affiliations

Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study

Sarvin Alizadeh Sadighi et al. Caspian J Intern Med. .

Abstract

Background: Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.

Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.

Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).

Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic _target for breast cancer. However, further investigation is needed to validate this claim.

Keywords: Breast cancer; Diabetes; ELISA; IGF-1; IGF-2.

PubMed Disclaimer

Conflict of interest statement

The author(s) received no financial support for the research.

Figures

Figure 1
Figure 1
Serum level of IGF-1 across the groups
Figure 2
Figure 2
Serum level of IGF-2 across the groups
Figure 3
Figure 3
Simplified view of IGF-1 and IGF-2 signaling. IGF-1 and IGF-2 have effects on cell growth, metabolism, proliferation and apoptosis by activating the IGF-1 receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Khodadadi E, Ataei N, Mofid MR. The effect and mechanism of action of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in human breast cancer; A systematic review. J Isfahan Med Sch. 2013;31:1560–7.
    1. Feng X, Lin J, Xing S, Liu W, Zhang G. Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma. BMC Cancer. 2017;17:90. - PMC - PubMed
    1. Oh H, Eliassen AH, Beck AH, et al. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. NPJ Breast Cancer. 2017;3:39. - PMC - PubMed
    1. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–16. - PubMed
    1. Espelund U, Cold S, Frystyk J, Ørskov H, Flyvbjerg A. Elevated free IGF2 levels in localized, early-stage breast cancer in women. Eur J Endocrinol. 2008;159:595. - PubMed

LinkOut - more resources

  NODES
INTERN 5
twitter 2